Drugs & Pharmaceuticals M&A » By The Online Investor Staff, updated Tue., Dec. 6, 8:07 AM
Recent mergers and acquisitions in the Drugs & Pharmaceuticals M&A category.
| This Slide: #10 of 100 |
Slide #10. Eli Lilly and Company — Novartis Animal Health
Acquirer:
Eli Lilly and Company (NYSE:LLY)
Acquiree:
Novartis Animal Health
Details:
Eli Lilly and Company (NYSE: LLY) today announced an agreement to acquire Novartis Animal Health for approximately $5.4 billion in an all-cash transaction that will strengthen and diversify Lilly's own animal health business, Elanco. Upon completion of the acquisition, Elanco will be the second-largest animal health company in terms of global revenue, will solidify its number two ranking in the U.S., and improve its position in Europe and the rest of the world.
Eli Lilly and Company discovers, develops, manufactures, and markets products in a single business segment: human pharmaceutical products. Co.'s products include: diabetes products, oncology products, immunology products, neuroscience products, and other therapies. Co.'s diabetes products include: Baqsimi®, Basaglar®, Humalog®, Humulin®, Jardiance®, Lyumjev®, Trajenta®, and Trulicity®. Co.'s oncology products include: Alimta®, Cyramza®, Erbitux®, Retevmo®, Tyvyt®, and Verzenio®. Co.'s immunology products include: Olumiant® and Taltz®. Co.'s neuroscience products include: Cymbalta®, Emgality®, Reyvow®, and Zyprexa®. Co.'s other therapies include: Bamlanivimab, Cialis®, and Forteo®.
Eli Lilly SEC Filing Email Alerts Service
Open the LLY Page at The Online Investor »
|
||||||||||||||||||||||||
Open the LLY Page at The Online Investor (in a new window) »
 Free LLY Email Alerts:
Get SEC Filing Alerts Get Dividend Alerts 
|
Avg. Broker Rec.
 
|
Strong Buy (3.70 out of 4) 64th percentile
(ranked higher than approx. 64% of all stocks covered)
Analysts' Target Price: LLY Stock Forecast Based on Zacks ABR data; powered by Xignite |
